C3L-00446
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 72.97193703
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.560
- INTERFERON_GAMMA_RESPONSE+0.520
- IL6_JAK_STAT3_SIGNALING+0.430
- TNFA_SIGNALING_VIA_NFKB+0.430
- ALLOGRAFT_REJECTION+0.370
- INFLAMMATORY_RESPONSE+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- NOTCH_SIGNALING+0.300
- APOPTOSIS+0.270
- COMPLEMENT+0.230
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.330
- CHOLESTEROL_HOMEOSTASIS-0.300
- OXIDATIVE_PHOSPHORYLATION-0.280
- PEROXISOME-0.260
- BILE_ACID_METABOLISM-0.230
- FATTY_ACID_METABOLISM-0.210
- UNFOLDED_PROTEIN_RESPONSE-0.210
- ADIPOGENESIS-0.190
- WNT_BETA_CATENIN_SIGNALING-0.190
- XENOBIOTIC_METABOLISM-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-A493-01A-11R-A24H-07 | — | cohortA1 | 0.850 |
| 2 | TCGA-MP-A4TI-01A-21R-A24X-07 | — | cohortA1 | 0.842 |
| 3 | ea0e56e4-d9e3-44a2-9bdb-2e98554f6bff | — | — | 0.841 |
| 4 | TCGA-44-7662-01A-11R-2066-07 | — | cohortA1 | 0.820 |
| 5 | SRR8613765 | — | D | 0.820 |
| 6 | MNG745 | — | — | 0.810 |
| 7 | X55db60cd.e752.41b4.aa3e.f68d676031f7 | — | cohortA1 | 0.807 |
| 8 | TCGA-55-6978-01A-11R-1949-07 | — | cohortA1 | 0.804 |
| 9 | TCGA-SY-A9G5-01A-11R-A38B-07 | — | — | 0.799 |
| 10 | TCGA-MP-A4TC-01A-11R-A24X-07 | — | cohortA1 | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |